{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:59:57Z","timestamp":1783299597836,"version":"3.54.6"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.neuropharm.2023.109442","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T02:29:58Z","timestamp":1675045798000},"page":"109442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Binding preference at the \u03bc-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1692-7199","authenticated-orcid":false,"given":"Bing","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie P.","family":"Le Rouzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-9909","authenticated-orcid":false,"given":"Meng-Hua M.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4880-2195","authenticated-orcid":false,"given":"Tiffany","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antara","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-8304","authenticated-orcid":false,"given":"Ying-Xian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109442_bib1","author":"Ahmad"},{"key":"10.1016\/j.neuropharm.2023.109442_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.03.042","article-title":"GPCR-mediated beta-arrestin activation deconvoluted with single-molecule precision","author":"Asher","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2023.109442_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2020.110553","article-title":"In vitro characterization of new psychoactive substances at the mu-opioid, CB1, 5HT1A, and 5-HT2A receptors-On-target receptor potency and efficacy, and off-target effects","volume":"317","author":"Astrand","year":"2020","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neuropharm.2023.109442_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/dta.2906","article-title":"Activation of the mu-opioid receptor by alicyclic fentanyls: changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure","volume":"13","author":"Astrand","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2023.109442_bib5","series-title":"Modeling Transmembrane Helix Contacts in GPCR","author":"Ballesteros","year":"1995"},{"key":"10.1016\/j.neuropharm.2023.109442_bib6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.tips.2018.09.006","article-title":"Pharmacological research as a key component in mitigating the opioid overdose crisis","volume":"39","author":"Baumann","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109442_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-021-05981-x","article-title":"Pharmacokinetics and pharmacodynamics of cyclopropylfentanyl in male rats","author":"Bergh","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109442_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/FTD.0000000000000617","article-title":"Distinguishing between cyclopropylfentanyl and crotonylfentanyl by methods commonly available in the forensic laboratory","volume":"41","author":"Bergh","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.neuropharm.2023.109442_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1098\/rspb.1983.0093","article-title":"Operational models of pharmacological agonism","volume":"220","author":"Black","year":"1983","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109442_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/syn.10277","article-title":"Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene Oprm","volume":"51","author":"Bolan","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2023.109442_bib11","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI126912","article-title":"Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids","volume":"129","author":"Cai","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2023.109442_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007394","article-title":"Molecular mechanisms of fentanyl mediated beta-arrestin biased signaling","volume":"16","author":"de Waal","year":"2020","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.neuropharm.2023.109442_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197734","article-title":"Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking","volume":"13","author":"Ellis","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2023.109442_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114293","article-title":"Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors","volume":"182","author":"Eshleman","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109442_bib15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/jat\/bky094","article-title":"Five postmortem case reports with qualitative analysis of cyclopropylfentanyl by LC-MS-MS","volume":"43","author":"Fagiola","year":"2019","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2023.109442_bib16","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jat\/bky035","article-title":"Analysis of fentanyl and 18 novel fentanyl analogs and metabolites by LC-MS-MS, and report of fatalities associated with methoxyacetylfentanyl and cyclopropylfentanyl","volume":"42","author":"Fogarty","year":"2018","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2023.109442_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neuropharm.2023.109442_bib18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41398-019-0625-0","article-title":"The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies","volume":"9","author":"Han","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109442_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14886","article-title":"Structural insights into micro-opioid receptor activation","volume":"524","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109442_bib20","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1093\/nar\/gkg460","article-title":"Comparative protein structure modeling by iterative alignment, model building and model assessment","volume":"31","author":"John","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2023.109442_bib21","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bph.12222","article-title":"Efficacy and ligand bias at the mu-opioid receptor","volume":"169","author":"Kelly","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109442_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"10","author":"Kliewer","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2023.109442_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41586-018-0219-7","article-title":"Structure of the micro-opioid receptor-Gi protein complex","volume":"558","author":"Koehl","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109442_bib24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52189","article-title":"Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism","volume":"9","author":"Lane","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2023.109442_bib25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00894-019-3999-2","article-title":"Molecular dynamics of fentanyl bound to mu-opioid receptor","volume":"25","author":"Lipinski","year":"2019","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.neuropharm.2023.109442_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2023.109442_bib27","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.neuropharm.2023.109442_bib28","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1021\/jacsau.1c00341","article-title":"Kinetics and mechanism of fentanyl dissociation from the mu-opioid receptor","volume":"1","author":"Mahinthichaichan","year":"2021","journal-title":"JACS Au"},{"key":"10.1016\/j.neuropharm.2023.109442_bib29","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1016\/j.bmcl.2011.05.008","article-title":"Generation of novel radiolabeled opiates through site-selective iodination","volume":"21","author":"Majumdar","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2023.109442_bib30","doi-asserted-by":"crossref","first-page":"19778","DOI":"10.1073\/pnas.1115231108","article-title":"Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects","volume":"108","author":"Majumdar","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109442_bib31","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.1021\/jm300305c","article-title":"Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated mu opioid receptor (MOR-1) splice variants","volume":"55","author":"Majumdar","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109442_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/nature10954","article-title":"Crystal structure of the micro-opioid receptor bound to a morphinan antagonist","author":"Manglik","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109442_bib33","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1021\/acs.jmedchem.6b01148","article-title":"Toward understanding the structural basis of partial agonism at the dopamine D3 receptor","volume":"60","author":"Michino","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109442_bib34","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10571-020-00973-5","article-title":"Mu opioids induce biased signaling at the full-length seven transmembrane C-terminal splice variants of the mu opioid receptor gene, Oprm1","volume":"41","author":"Narayan","year":"2021","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109442_bib35","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","article-title":"Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls - United States, 2019-2020","volume":"70","author":"O'Donnell","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2023.109442_bib36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.120.000189","article-title":"Pharmacological comparison of mitragynine and 7-hydroxymitragynine: in vitro affinity and efficacy for mu-opioid receptor and opioid-like behavioral effects in rats","volume":"376","author":"Obeng","year":"2021","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109442_bib37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.neuropharm.2023.109442_bib38","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1124\/mol.56.2.396","article-title":"Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms","volume":"56","author":"Pan","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109442_bib39","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1073\/pnas.0811586106","article-title":"Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions","volume":"106","author":"Pan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109442_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25204636","article-title":"Molecular modeling of \u03bc opioid receptor ligands with various functional properties: PZM21, SR-17018, morphine, and fentanyl-simulated interaction patterns confronted with experimental data","volume":"25","author":"Podlewska","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2023.109442_bib41","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/acs.jcim.0c00890","article-title":"Structural assessment of agonist efficacy in the \u03bc-opioid receptor: morphine and fentanyl elicit different activation patterns","volume":"61","author":"Ricarte","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.neuropharm.2023.109442_bib42","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1021\/acs.jctc.8b01026","article-title":"OPLS3e: extending Force Field Coverage for Drug-Like Small Molecules","volume":"15","author":"Roos","year":"2019","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.neuropharm.2023.109442_bib43","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2023.109442_bib44","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1124\/jpet.120.000349","article-title":"Manipulating pharmacodynamic efficacy with agonist + antagonist mixtures: in vitro and in vivo studies with opioids and cannabinoids","volume":"376","author":"Selley","year":"2021","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109442_bib45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109442_bib46","doi-asserted-by":"crossref","first-page":"40989","DOI":"10.1074\/jbc.M206801200","article-title":"Beta 2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch","volume":"277","author":"Shi","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2023.109442_bib47","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jpain.2014.08.010","article-title":"The fentanyl story","volume":"15","author":"Stanley","year":"2014","journal-title":"J. Pain"},{"key":"10.1016\/j.neuropharm.2023.109442_bib48","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.bbamem.2016.01.010","article-title":"Computational approaches to detect allosteric pathways in transmembrane molecular machines","volume":"1858","author":"Stolzenberg","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2023.109442_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/PAF.0000000000000722","article-title":"Thirteen cases of valeryl fentanyl in Michigan: a call for expanding opioid testing","volume":"42","author":"Ton","year":"2021","journal-title":"Am. J. Forensic Med. Pathol"},{"key":"10.1016\/j.neuropharm.2023.109442_bib50","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00204-022-03276-4","article-title":"Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole 'nitazene' synthetic opioid","volume":"96","author":"Vandeputte","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.neuropharm.2023.109442_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuropharm.2019.03.023","article-title":"Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances","volume":"151","author":"Varshneya","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109442_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113910","article-title":"Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform","volume":"177","author":"Vasudevan","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109442_bib53","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41467-021-21262-9","article-title":"How mu-opioid receptor recognizes fentanyl","volume":"12","author":"Vo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2023.109442_bib54","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.neuropharm.2019.02.007","article-title":"Oxycodone-like discriminative stimulus effects of fentanyl-related emerging drugs of abuse in mice","volume":"150","author":"Walentiny","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109442_bib55","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jat\/bkab066","article-title":"Acute intoxications involving valerylfentanyl identified at the New York city office of chief medical examiner","volume":"45","author":"Walsh","year":"2021","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2023.109442_bib56","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.csbj.2022.05.013","article-title":"A comprehensive evaluation of the potential binding poses of fentanyl and its analogs at the micro-opioid receptor","volume":"20","author":"Xie","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.neuropharm.2023.109442_bib57","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1073\/pnas.1419183112","article-title":"Stabilization of morphine tolerance with long-term dosing: association with selective upregulation of mu-opioid receptor splice variant mRNAs","volume":"112","author":"Xu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109442_bib58","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1172\/JCI88760","article-title":"Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine","volume":"127","author":"Xu","year":"2017","journal-title":"J. Clin. Invest."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823000321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823000321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:21:36Z","timestamp":1758439296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823000321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":58,"alternative-id":["S0028390823000321"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109442","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Binding preference at the \u03bc-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109442"}}